ArticleInternational journal of general medicine2026
Adjunctive Tirofiban is not Associated with Reduced 30-Day Ischemic Events in NSTE-ACS Patients with Complex Coronary Lesions After PCI: A Retrospective Observational Cohort Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glycoprotein IIb/IIIa inhibitors are generally reserved for selected high-thrombotic-risk or bailout percutaneous coronary intervention (PCI) scenarios, but their routine value in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients with anatomically complex coronary lesions remains uncertain. We evaluated adjunctive tirofiban in patients with left main, chronic total occlusion, bifurcation, ostial, long, or severely calcified lesions, while excluding confirmed intracoronary thrombus, no-reflow, or slow-flow. Methods: This retrospective observational study included 1462 NSTE-ACS patients undergoing PCI with stent implantation. Patients receiving dual antiplatelet therapy (DAPT) with or without tirofiban were compared. The efficacy endpoint was 30-day composite ischemic events, and the safety endpoint was any bleeding. Multivariable adjustment and 1:1 propensity score matching (PSM) were performed. Results: In the overall cohort, tirofiban was not associated with lower ischemic risk (9.35% vs 9.42%; unadjusted OR 0.99, 95% CI 0.68-1.45; adjusted OR 1.02, 95% CI 0.68-1.52). Bleeding was numerically higher but not significant (3.94% vs 3.59%; adjusted OR 1.08, 95% CI 0.58-2.01). After matching, 431 patients per group were retained. Ischemic events (10.21% vs 9.51%; OR 1.08, 95% CI 0.69-1.69) and bleeding events (5.10% vs 3.71%; OR 1.40, 95% CI 0.72-2.69) remained non-significantly higher with tirofiban. No significant subgroup interactions were observed. Conclusion: In this selected non-thrombotic complex-lesion NSTE-ACS cohort, routine adjunctive tirofiban was not associated with improved 30-day ischemic outcomes. Anatomical complexity alone may be insufficient to justify routine "add-on" tirofiban in the absence of thrombotic or bailout indications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.